Lacosamide — Membership Pricing

Other medications in Neurological

• Lasmiditan
• Meclizine
• Memantine
• Midazolam Nasal
• Natalizumab (Neurology)
• Nusinersen
• Ocrelizumab
• Ofatumumab

About Lacosamide

Lacosamide is an important antiepileptic drug primarily used to treat focal onset seizures (also known as partial onset seizures) in patients aged one month and older. It can be prescribed alone (monotherapy) or in combination with other anti-epileptic drugs (adjunctive therapy). More recently, it has also been approved for the treatment of generalized tonic-clonic seizures. These seizures originate in one part of the brain and can sometimes spread, affecting consciousness or motor function. For many individuals living with epilepsy, lacosamide offers a significant improvement in seizure control, contributing to a better quality of life.

Lacosamide belongs

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lacosamide is approved for (FDA label)

Lacosamide oral solution is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures Lacosamide oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures Lacosamide oral solution is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lacosamide (FDA label)

Lacosamide oral solution, USP • 10 mg/mL: clear, colorless to yellow or yellow-brown, strawberry-flavored liquid 10 mg/mL oral solution (3)

Source: FDA prescribing information (DailyMed). Set ID: 5b10986e-0809-b6d1-e063-6394a90a5738. SPL document ID: 5b10986e-080a-b6d1-e063-6394a90a5738. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lacosamide (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Behavior and Ideation [ see Warnings and Precautions ( 5.1 ) ] Dizziness and Ataxia [ see Warnings and Precautions ( 5.2 ) ] Cardiac Rhythm and Conduction Abnormalities [ see Warnings and Precautions ( 5.3 ) ] Syncope [ see Warnings and Precautions ( 5.4 ) ] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions [ see Warnings and Precautions ( 5.6 ) ] Adjunctive therapy: Most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence ( 6.1 ) Monotherapy: Most common adverse reactions are similar to those seen in adjunctive therapy studies ( 6.1 ) Pediatric patients: Adverse reactions are similar to those seen in adult patients ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AvkARE at 1-855-361-3993 or www.avkare.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 5b10986e-0809-b6d1-e063-6394a90a5738. SPL document ID: 5b10986e-080a-b6d1-e063-6394a90a5738. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lacosamide (FDA label)

Monitor patients for suicidal behavior and ideation ( 5.1 ) Lacosamide oral solution may cause dizziness and ataxia ( 5.2 ) Cardiac Rhythm and Conduction Abnormalities: Obtaining ECG before beginning and after titration to steady-state maintenance is recommended in patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction; closely monitor these patients ( 5.3 , 7.2 ) Lacosamide oral solution may cause syncope ( 5.4 ) Lacosamide oral solution should be gradually withdrawn to minimize the potential of increased seizure frequency ( 5.5 ) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/ Multi-Organ Hypersensitivity: Discontinue if no alternate etiology ( 5.6 ) 5.1 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including Lacosamide oral solution, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.

Source: FDA prescribing information (DailyMed). Set ID: 5b10986e-0809-b6d1-e063-6394a90a5738. SPL document ID: 5b10986e-080a-b6d1-e063-6394a90a5738. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lacosamide (FDA label)

7.1 Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to Lacosamide oral solution. Dose reduction may be necessary in these patients. 7.2 Concomitant Medications that Affect Cardiac Conduction Lacosamide oral solution should be used with caution in patients on concomitant medications that affect cardiac conduction (sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers) including those that prolong PR interval (including sodium channel blocking AEDs), because of a risk of AV block, bradycardia, or ventricular tachyarrhythmia. In such patients, obtaining an ECG before beginning Lacosamide oral solution, and after Lacosamide oral solution is titrated to steady-state, is recommended. In addition, these patients should be closely monitored if they are administered lacosamide through the intravenous route [ see Warnings and Precautions ( 5.3 ) ].

Source: FDA prescribing information (DailyMed). Set ID: 5b10986e-0809-b6d1-e063-6394a90a5738. SPL document ID: 5b10986e-080a-b6d1-e063-6394a90a5738. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.